Last updated: August 27, 2026
Tiagabine hydrochloride is an established immediate-release small-molecule antiseizure drug with limited remaining originator exclusivity and a genericized U.S. market. The strongest commercial opportunities are differentiated oral formulations, including lactose-free tablets, pediatric liquids, orally disintegrating tablets, and potentially modified-release products. A conventional generic tablet remains commercially viable only where manufacturing cost, supply reliability, regulatory execution, and channel access are competitive.
What is the commercial status of tiagabine hydrochloride?
Tiagabine hydrochloride is the active pharmaceutical ingredient in Gabitril, originally developed by Novo Nordisk and later commercialized in the United States by Cephalon. Teva acquired Cephalon in 2011. The product is approved as adjunctive therapy for partial seizures in patients aged 12 years and older. It is not approved as monotherapy for epilepsy.[1]
| Attribute |
Tiagabine hydrochloride |
| Brand |
Gabitril |
| U.S. application |
NDA 020646 |
| Therapeutic class |
Antiseizure medication |
| Mechanism |
GABA reuptake inhibition through GAT-1 inhibition |
| Approved dosage form |
Immediate-release tablets |
| Strengths |
2 mg, 4 mg, 12 mg, and 16 mg |
| U.S. approval |
1997 |
| Primary indication |
Adjunctive treatment of partial seizures |
| Generic status |
Generic tablets have entered the U.S. market |
| Biologic status |
Small molecule; biosimilar pathway does not apply |
| Commercial concentration |
Mature, niche epilepsy market |
Gabitril’s clinical use is narrower than that of levetiracetam, lamotrigine, or oxcarbazepine. Tiagabine is generally prescribed as an adjunctive therapy, which limits total addressable volume. The product remains commercially relevant because epilepsy treatment is chronic, switching can be clinically sensitive, and prescribers may retain older therapies for patients who are stable on treatment.
What excipients are used in tiagabine hydrochloride tablets?
The Gabitril labeling identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, silicon dioxide, and stearic acid. The coating system includes standard film-coating materials.[1]
The reference formulation provides a practical baseline for an ANDA or lifecycle product:
| Formulation function |
Likely reference-product approach |
Strategic implication |
| Diluent |
Lactose monohydrate |
Supports low-cost direct compression or granulation but creates lactose-intolerance and labeling considerations |
| Dry binder and compression aid |
Microcrystalline cellulose |
Provides tablet strength and robust manufacturability |
| Disintegrant or processing aid |
Pregelatinized starch |
Supports disintegration and compactibility |
| Glidant |
Silicon dioxide |
Improves powder flow and content uniformity |
| Lubricant |
Stearic acid |
Supports ejection and tooling performance |
| Film coating |
Hypromellose-based or equivalent coating system |
Allows strength differentiation and protects tablet appearance |
| Colorant or opacifier |
Product-specific coating materials |
May support strength identification and patient adherence |
The exact excipient composition should be confirmed against the current approved labeling and reference-product samples before regulatory or freedom-to-operate decisions. Excipient selection can differ between strengths and manufacturing sites.
Which excipient strategies offer the strongest commercial opportunities?
The best opportunities are formulations that address a defined patient, caregiver, pharmacy, or manufacturing problem. Replacing excipients without improving performance is unlikely to create durable commercial value in a mature generic market.
Lactose-free tiagabine tablets
A lactose-free formulation is the most straightforward differentiation opportunity. The reference product uses lactose monohydrate, creating an opening for tablets based on mannitol, dibasic calcium phosphate, anhydrous lactose alternatives, or a combination of microcrystalline cellulose and starch-based excipients.
A lactose-free product could target:
- Patients with lactose intolerance or excipient sensitivity
- Hospital formularies with excipient restrictions
- Pediatric and geriatric patients with dietary limitations
- International markets where lactose labeling is commercially sensitive
- Specialty pharmacies seeking differentiated generic products
The formulation must preserve hardness, friability, dissolution, content uniformity, and stability across all four strengths. Tiagabine products use low-dose strengths, particularly 2 mg and 4 mg, where blend uniformity and segregation control are more important than simply achieving tablet weight.
Pediatric oral liquid
Tiagabine is approved for patients aged 12 years and older, limiting the commercial value of an infant or young-child formulation under the current label. A liquid could still improve administration for adolescents, patients with dysphagia, and patients receiving enteral nutrition.
A liquid formulation would require careful control of:
- API solubility and chemical stability
- pH-dependent degradation
- Taste and mouthfeel
- Preservative compatibility
- Container closure performance
- Dose uniformity after shaking
- Compatibility with nasogastric or gastrostomy tubes
The most practical product would likely be an immediate-release oral solution or suspension rather than a complex delivery system. A liquid could be pursued through an ANDA only if the product meets the applicable dosage-form requirements. If the formulation introduces a clinically meaningful difference in route, dosing flexibility, or labeling, a 505(b)(2) strategy may be more appropriate.
Orally disintegrating tablet
An orally disintegrating tablet could improve administration for patients who have difficulty swallowing conventional tablets. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and suitable taste-masking systems are common formulation tools.
Key risks include:
- Bitter or unpleasant API taste
- Low-dose content uniformity
- Mechanical fragility
- Moisture sensitivity
- Packaging cost
- Whether the product qualifies as an ODT under FDA performance expectations
ODT development is more attractive for the 2 mg and 4 mg strengths, where the tablet can be engineered around rapid dispersion and dose flexibility. The product would need packaging that protects against humidity while remaining convenient for chronic use.
Sprinkle or dispersible tablet
A dispersible or sprinkle formulation could address patients who cannot swallow tablets but can take medication with soft food. This approach may be less expensive than an ODT and could provide a practical pediatric-adjacent positioning strategy.
The main technical issue is dose recovery. The product must demonstrate that the full dose can be delivered after dispersion in an approved vehicle and that the API does not adhere excessively to food, cups, syringes, or feeding tubes.
Modified-release product
Modified-release tiagabine could reduce dosing frequency and smooth plasma exposure. The commercial opportunity is larger than for a simple excipient substitution, but the regulatory and clinical burden is also higher.
A modified-release product could use:
- Hydrophilic matrix polymers
- Insoluble matrix systems
- Multiparticulate beads
- Functional coatings
- Osmotic or diffusion-controlled systems
The product would likely require a 505(b)(2) application unless an approved reference for the same modified-release product exists. Bioequivalence may require comparative pharmacokinetic studies under fed and fasted conditions, and possibly clinical evaluation if exposure or dosing differs materially.
What excipient risks are important for tiagabine hydrochloride?
Tiagabine hydrochloride formulation development should focus on chemical stability, low-dose uniformity, dissolution, and patient acceptability.
Low-dose content uniformity
The 2 mg and 4 mg tablets contain relatively small API quantities. Direct blending can create segregation risk, particularly when API particle size differs materially from the principal diluent. Wet granulation, ordered mixing, spray layering, or a premix strategy may improve uniformity.
A commercial formulation should establish:
- API particle-size distribution
- Blend uniformity across scale
- Sampling representativeness
- Segregation during transfer and compression
- Assay and content-uniformity capability
- Stability of low-dose tablets over shelf life
Salt, pH, and moisture behavior
Tiagabine hydrochloride is a salt form. The formulation should evaluate the effect of excipient microenvironmental pH, water activity, and residual moisture on assay, impurities, dissolution, and physical form.
High-moisture excipients can create stability risk if the API is sensitive to hydrolysis or if moisture changes tablet disintegration. Hygroscopic excipients may also complicate packaging and accelerate coating or tablet softening.
Excipient compatibility
Compatibility screening should include lactose, mannitol, microcrystalline cellulose, starches, crospovidone, croscarmellose sodium, magnesium stearate, stearic acid, colloidal silicon dioxide, coating polymers, and common preservatives for liquid formulations.
The development program should use stressed binary mixtures and accelerated stability studies. Analytical methods should distinguish API degradation from excipient-related impurities and coating components.
Dissolution performance
The reference product establishes the principal bioequivalence target. A formulation that changes wetting, particle dispersion, tablet porosity, or disintegration can alter the dissolution profile even if the drug substance is highly soluble.
A successful generic strategy should use comparative dissolution across multiple media and pH conditions. Formulation changes that improve rapid disintegration must not create excessive early release or a materially different profile.
What patents protect tiagabine hydrochloride products?
The original composition-of-matter and product exclusivity for tiagabine hydrochloride are no longer the primary commercial barriers in the U.S. The product was approved in 1997, and generic tiagabine tablets have been marketed for years.
The relevant intellectual-property categories are:
- Original API and salt patents, which are generally expired or commercially exhausted.
- Formulation patents covering modified release, taste masking, dispersible delivery, or specific excipient combinations.
- Method-of-use patents covering epilepsy treatment or dosing approaches.
- Manufacturing patents covering crystallization, particle engineering, impurity control, or scale-up.
- Device or packaging patents for liquid, ODT, multiparticulate, or adherence-oriented products.
For a new formulation, the commercially meaningful patent strategy would focus on a narrow combination of formulation and performance claims. Broad claims to a conventional immediate-release tablet containing tiagabine hydrochloride would face substantial validity and obviousness risk.
What is the Orange Book status of tiagabine?
The Orange Book is the principal FDA source for approved drug products, therapeutic equivalence evaluations, patents, and regulatory exclusivity. Gabitril is listed under NDA 020646, while generic products are listed under abbreviated applications.[2]
For current diligence, the relevant issues are:
- Whether any unexpired Gabitril patent remains listed
- Whether the listed product has pediatric or other regulatory exclusivity
- Whether generic applicants submitted Paragraph IV certifications
- Whether any listed patent covers the proposed dosage form
- Whether the proposed product can rely on a Paragraph III certification or a certification that no relevant patent is listed
A conventional generic tablet faces a lower patent barrier than a differentiated formulation. An ODT, oral liquid, sprinkle product, or modified-release product may require a separate patent and regulatory analysis because the formulation could fall outside the scope of the listed immediate-release product.
When does tiagabine lose exclusivity?
Tiagabine has already lost its principal U.S. market exclusivity. FDA approval occurred in 1997, and the product’s generic-entry period has passed. Current opportunity therefore depends on product differentiation rather than originator exclusivity.
| Exclusivity category |
Tiagabine status |
| New chemical entity exclusivity |
Expired |
| Original composition-of-matter protection |
No longer the principal commercial barrier |
| Conventional immediate-release generic entry |
Established |
| Biosimilar exclusivity |
Not applicable |
| New formulation exclusivity |
Potentially available if a qualifying product is approved |
| Orphan exclusivity |
Not the principal basis of the original product opportunity |
| Pediatric exclusivity |
Must be verified in the current Orange Book |
A qualifying new clinical investigation could support three years of FDA exclusivity for a new formulation or indication under the Hatch-Waxman framework, but the scope would depend on the type of approval and the exclusivity-generating study. Five-year NCE exclusivity would not apply to a product based on the existing active moiety.
Which companies are challenging tiagabine, and what is the litigation risk?
Generic competition has already reduced the litigation value of the conventional tablet. The principal risks for a new entrant are commercial rather than patent-litigation risks:
- Price compression from established generic suppliers
- Limited prescribing growth
- Pharmacy substitution
- Low annual prescription volume
- Supply interruptions caused by small market size
- Contracting disadvantages versus larger generic companies
Paragraph IV litigation is more relevant if a company launches a new protected formulation. A formulation patent could attract an ANDA challenge if the product has sufficient market value, but the expected litigation economics are weaker than for high-revenue central nervous system products.
A settlement agreement would be commercially meaningful only if it established an authorized-generic arrangement, a licensed launch date, or a market-sharing restriction. No material settlement should be assumed without a verified court docket, FDA Orange Book entry, or company filing.
How strong is the tiagabine patent estate?
The patent estate for conventional tiagabine tablets is weak from a lifecycle-management perspective because the product is old, genericized, and based on a standard immediate-release dosage form.
| Patent category |
Commercial strength |
| Original API patent |
Low for current U.S. entry |
| Conventional tablet composition |
Low unless a narrow formulation claim survives |
| Method of use |
Moderate only if a specific, enforceable use remains |
| Modified release |
Potentially strong if supported by clinical and pharmacokinetic data |
| ODT or taste masking |
Moderate, but vulnerable to design-around |
| Oral liquid |
Moderate if the formulation has unusual stability or delivery claims |
| Manufacturing process |
Moderate where impurity control or crystallization is difficult to replicate |
| Packaging and adherence system |
Usually limited unless combined with a clinically meaningful feature |
The strongest patent program would combine composition claims with performance claims, such as rapid dispersion, specified dissolution, stability under defined conditions, or delivery through a feeding tube. Single-feature excipient claims are easier for competitors to avoid.
What commercial opportunities exist by geography?
The United States offers the clearest ANDA pathway but also the most mature generic competition. European and other regulated markets may provide opportunities for differentiated dosage forms, particularly if local products lack liquid, ODT, or lactose-free options.
United States
The U.S. opportunity is strongest for:
- Reliable supply of all four strengths
- Authorized-generic or specialty-pharmacy distribution
- Lactose-free tablets
- ODT or dispersible products
- Contract manufacturing for epilepsy-focused companies
Europe
European opportunities depend on national reimbursement, prescription volume, and the status of local marketing authorizations. A liquid or ODT may have greater value where pediatric and geriatric administration needs are emphasized, but market fragmentation raises registration and commercialization costs.
Emerging markets
Cost-focused immediate-release tablets may be viable where generic competition is limited. The main barriers are API sourcing, local registration, pharmacopoeial compliance, serialization, and reliable distribution.
How should a company prioritize tiagabine formulation projects?
A practical prioritization is:
| Rank |
Product concept |
Regulatory complexity |
Commercial outlook |
| 1 |
Lactose-free immediate-release tablet |
Low to moderate |
Moderate |
| 2 |
Supply-secure conventional generic |
Low |
Low to moderate |
| 3 |
ODT |
Moderate |
Moderate |
| 4 |
Dispersible or sprinkle tablet |
Moderate |
Moderate |
| 5 |
Oral liquid |
Moderate to high |
Selective |
| 6 |
Modified-release product |
High |
Potentially high, but riskier |
The highest probability-adjusted project is a lactose-free or otherwise excipient-differentiated immediate-release tablet supported by strong manufacturing economics. The highest upside project is modified release, but it requires more clinical, pharmacokinetic, patent, and commercial investment.
Licensing opportunities may arise from companies with tiagabine API capacity, regional marketing rights, or formulation platforms for antiseizure drugs. A transaction should prioritize supply control and regulatory readiness over nominal patent breadth because the conventional product market is mature.
Key Takeaways
- Tiagabine hydrochloride is a genericized small-molecule antiseizure drug marketed originally as Gabitril.
- The reference product uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, silicon dioxide, and stearic acid.
- Lactose-free tablets are the most practical excipient-led opportunity.
- ODT, dispersible, sprinkle, and oral-liquid products offer differentiated administration but require stronger bioequivalence and stability packages.
- Modified release has the greatest potential value and the highest development risk.
- The central formulation challenge is low-dose content uniformity in the 2 mg and 4 mg strengths.
- Biosimilar risk does not apply because tiagabine is a small molecule.
- Conventional patent protection is commercially weak; new value depends on formulation, manufacturing, or delivery claims.
- Generic launch economics are constrained by mature competition, limited indication breadth, and modest market size.
- Regulatory and commercial diligence should center on the current Orange Book, approved labeling, active generic applicants, API availability, and actual payer demand.
FAQs
Can tiagabine hydrochloride be formulated without lactose?
Yes. Mannitol, microcrystalline cellulose, starch derivatives, and calcium phosphate systems can replace lactose, subject to dissolution, stability, tablet-strength, and bioequivalence requirements.
Is tiagabine hydrochloride suitable for an orally disintegrating tablet?
Yes, but taste masking, low-dose uniformity, moisture protection, mechanical strength, and rapid dispersion must be demonstrated. The 2 mg and 4 mg strengths are logical development targets.
Does tiagabine hydrochloride have biosimilar competition?
No. Tiagabine hydrochloride is a synthetic small molecule and competes through generic-drug pathways, not biosimilar regulation.
Could a tiagabine oral liquid obtain new exclusivity?
Potentially. A qualifying new formulation supported by required clinical investigations may receive limited FDA exclusivity, but the applicable period and scope depend on the approval basis and exclusivity-generating studies.
What is the most defensible patent strategy for a new tiagabine product?
A layered strategy covering a specific excipient system, measurable dissolution or dispersion performance, stability characteristics, and a clinically relevant administration method is more defensible than a broad claim to a conventional tiagabine tablet.
References
- U.S. Food and Drug Administration. (2012). Gabitril (tiagabine hydrochloride) tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. National Library of Medicine. (n.d.). DailyMed: Tiagabine hydrochloride and Gabitril drug labeling.
- U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry.
